D Rosenberg

4.0k total citations · 2 hit papers
90 papers, 2.5k citations indexed

About

D Rosenberg is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, D Rosenberg has authored 90 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 14 papers in Surgery and 14 papers in Pathology and Forensic Medicine. Recurrent topics in D Rosenberg's work include Pulmonary Hypertension Research and Treatments (16 papers), Systemic Sclerosis and Related Diseases (13 papers) and Hepatitis C virus research (6 papers). D Rosenberg is often cited by papers focused on Pulmonary Hypertension Research and Treatments (16 papers), Systemic Sclerosis and Related Diseases (13 papers) and Hepatitis C virus research (6 papers). D Rosenberg collaborates with scholars based in United States, Switzerland and United Kingdom. D Rosenberg's co-authors include Christopher P. Denton, Anna S. Lok, Oliver Distler, Harbajan Chadha‐Boreham, Martin Doelberg, Vallerie V. McLaughlin, Voon H Ong, Svetlana I. Nihtyanova, Pia Moinzadeh and Benjamin Schreiber and has published in prestigious journals such as Gastroenterology, Brain Research and CHEST Journal.

In The Last Decade

D Rosenberg

84 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

2013 541 citations Gerry Coghlan, Christopher P. Denton et al. Annals of the Rheumatic Diseases profile →
Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis

2014 325 citations D Rosenberg, Christopher P. Denton et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D Rosenberg United States	22	1.2k	1.0k	799	422	297	90	2.5k
B Devulder France	24	756 0.7×	644 0.6×	1.2k 1.4×	47 0.1×	272 0.9×	188	2.9k
Douglass Chapman United States	28	701 0.6×	259 0.3×	325 0.4×	168 0.4×	123 0.4×	62	2.7k
Nils Feltelius Sweden	32	197 0.2×	1.0k 1.0×	565 0.7×	109 0.3×	172 0.6×	79	4.1k
Mohammed Tikly South Africa	26	258 0.2×	614 0.6×	312 0.4×	99 0.2×	159 0.5×	110	2.5k
Norberto Ortego‐Centeno Spain	29	429 0.4×	578 0.6×	435 0.5×	59 0.1×	186 0.6×	191	3.0k
José Luís Callejas-Rubio Spain	27	426 0.4×	398 0.4×	276 0.3×	73 0.2×	140 0.5×	143	2.2k
Clive Kelly United Kingdom	29	1.3k 1.1×	452 0.4×	557 0.7×	39 0.1×	70 0.2×	112	2.8k
T G Allen-Mersh United Kingdom	29	592 0.5×	281 0.3×	200 0.3×	486 1.2×	69 0.2×	77	3.0k
Riccardo Morganti Italy	27	579 0.5×	137 0.1×	465 0.6×	171 0.4×	136 0.5×	233	2.6k
Christophe Richez France	37	298 0.3×	551 0.5×	356 0.4×	122 0.3×	155 0.5×	148	4.6k

Countries citing papers authored by D Rosenberg

Since Specialization

Citations

This map shows the geographic impact of D Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Rosenberg more than expected).

Fields of papers citing papers by D Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Rosenberg. The network helps show where D Rosenberg may publish in the future.

Co-authorship network of co-authors of D Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of D Rosenberg. A scholar is included among the top collaborators of D Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Rosenberg. D Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenberg, D, et al.. (2024). Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks. Pharmacoepidemiology and Drug Safety. 33(4). e5778–e5778.

Kim, Nick H., Kelly Chin, Vallerie V. McLaughlin, et al.. (2024). Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies. Pulmonary Therapy. 10(1). 85–107. 5 indexed citations

Khan, Mohammad Daud, D Rosenberg, Mark Phillips, et al.. (2022). Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Survey of Ophthalmology. 67(5). 1346–1363. 16 indexed citations

Rosenberg, D, et al.. (2021). Long-term efficacy and treatment burden of treat-and-extend versus fixed or PRN regimens for nAMD: a systematic review and meta-analysis.. Investigative Ophthalmology & Visual Science. 62(8). 3109–3109. 1 indexed citations

Patterson, Marc C., William S. Garver, Jackie Imrie, et al.. (2020). Long‐term survival outcomes of patients with Niemann‐Pick disease type C receiving miglustat treatment: A large retrospective observational study. Journal of Inherited Metabolic Disease. 43(5). 1060–1069. 42 indexed citations

Mihai, Carina, Rucsandra Dobrotă, Diana Bonderman, et al.. (2017). Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Annals of the Rheumatic Diseases. 77(1). 128–132. 21 indexed citations

Frantz, Robert P., Robert Schilz, Murali M. Chakinala, et al.. (2014). Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study. CHEST Journal. 147(2). 484–494. 37 indexed citations

Jick, Susan S., et al.. (2012). Incidence of the Pneumoconioses in the United Kingdom General Population between 1997 and 2008. Respiration. 84(3). 200–206. 9 indexed citations

Jacobs, Wouter, Anco Boonstra, Monika Brand, et al.. (2010). Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. The Journal of Heart and Lung Transplantation. 29(10). 1150–1158. 7 indexed citations

10.

Ivy, D. Dunbar, et al.. (2010). Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings. The American Journal of Cardiology. 106(9). 1332–1338. 85 indexed citations

11.

Simon, Bárbara, Cheryl Marco, D Rosenberg, et al.. (2008). A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS. International Journal of Clinical Practice. 62(12). 1858–1863. 9 indexed citations

12.

Funk, Michele L. Jonsson, et al.. (2005). Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology. 20(3). 433–440. 7 indexed citations

13.

Robinson, Noah Jamie, et al.. (2005). Chronic hepatitis B virus infection in the Asia–Pacific region and Africa: Review of disease progression. Journal of Gastroenterology and Hepatology. 20(6). 833–843. 72 indexed citations

14.

Xu, Biao, et al.. (2003). Chronic hepatitis B: A long‐term retrospective cohort study of disease progression in Shanghai, China. Journal of Gastroenterology and Hepatology. 18(12). 1345–1352. 40 indexed citations

15.

Rosenberg, D, William McCarthy, Charles K.N. Chan, et al.. (2001). Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS. 15(2). 211–214. 21 indexed citations

16.

Rosenberg, D, et al.. (2001). La synovite villonodulaire et pigmentée. Forme diffuse et forme localisée chez l’enfant. Archives de Pédiatrie. 8(4). 381–384. 17 indexed citations

17.

Irwin, Debra E., Lisa B. Weatherby, Wen‐Yi Huang, et al.. (2001). Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Services Research. 1(1). 8–8. 42 indexed citations

18.

Rosenberg, D, Richard Kahn, Patricia Kissinger, et al.. (1999). Networks of Persons With Syphilis and at Risk for Syphilis in Louisiana: Evidence of Core Transmitters. Sexually Transmitted Diseases. 26(2). 108–114. 28 indexed citations

19.

Jankauskienė, Augustina, et al.. (1997). Multicystic dysplastic kidney associated with Waardenburg syndrome type 1. Pediatric Nephrology. 11(6). 744–745. 8 indexed citations

20.

Rosenberg, D, et al.. (1969). Encéphalopathie avec troubles du métabolisme des purines. Observation familiale.. 26(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact